Literature DB >> 18669897

Use of ordinal outcomes in vascular prevention trials: comparison with binary outcomes in published trials.

Philip M W Bath1, Chamila Geeganage, Laura J Gray, Timothy Collier, Stuart Pocock.   

Abstract

BACKGROUND AND
PURPOSE: Vascular prevention trials mostly count "yes/no" (binary) outcome events, eg, stroke/no stroke. Analysis of ordered categorical vascular events (eg, fatal stroke/nonfatal stroke/no stroke) is clinically relevant and could be more powerful statistically. Although this is not a novel idea in the statistical community, ordinal outcomes have not been applied to stroke prevention trials in the past.
METHODS: Summary data on stroke, myocardial infarction, combined vascular events, and bleeding were obtained by treatment group from published vascular prevention trials. Data were analyzed using 10 statistical approaches which allow comparison of 2 ordinal or binary treatment groups. The results for each statistical test for each trial were then compared using Friedman 2-way analysis of variance with multiple comparison procedures.
RESULTS: Across 85 trials (335 305 subjects) the test results differed substantially so that approaches which used the ordinal nature of stroke events (fatal/nonfatal/no stroke) were more efficient than those which combined the data to form 2 groups (P<0.0001). The most efficient tests were bootstrapping the difference in mean rank, Mann-Whitney U test, and ordinal logistic regression; 4- and 5-level data were more efficient still. Similar findings were obtained for myocardial infarction, combined vascular outcomes, and bleeding. The findings were consistent across different types, designs and sizes of trial, and for the different types of intervention.
CONCLUSIONS: When analyzing vascular events from prevention trials, statistical tests which use ordered categorical data are more efficient and are more likely to yield reliable results than binary tests. This approach gives additional information on treatment effects by severity of event and will allow trials to be smaller.

Entities:  

Mesh:

Year:  2008        PMID: 18669897     DOI: 10.1161/STROKEAHA.107.509893

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  16 in total

1.  A unified framework for the comparison of treatments with ordinal responses.

Authors:  Tong-Yu Lu; Wai-Yin Poon; Siu Hung Cheung
Journal:  Psychometrika       Date:  2013-11-28       Impact factor: 2.500

2.  Impact of GOS misclassification on ordinal outcome analysis of traumatic brain injury clinical trials.

Authors:  Juan Lu; Anthony Marmarou; Kate L Lapane
Journal:  J Neurotrauma       Date:  2011-09-21       Impact factor: 5.269

3.  The relative efficiency of time-to-threshold and rate of change in longitudinal data.

Authors:  M C Donohue; A C Gamst; R G Thomas; R Xu; L Beckett; R C Petersen; M W Weiner; P Aisen
Journal:  Contemp Clin Trials       Date:  2011-04-30       Impact factor: 2.226

4.  Analysis of the compliance and the related influence factors in the follow-up process of surveillance for Creutzfeldt-Jakob disease in China.

Authors:  Xiao-Mei Zhang; Kang Xiao; Wei Zhou; Cao Chen; Yan Lv; Li-Na Chen; Qi Shi; Xiao-Ping Dong
Journal:  Prion       Date:  2014       Impact factor: 3.931

5.  Infarct volume predicts delayed recovery in patients with subarachnoid hemorrhage and severe neurological deficits.

Authors:  Neil F Rosenberg; Storm M Liebling; Adam R Kosteva; Matthew B Maas; Shyam Prabhakaran; Andrew M Naidech
Journal:  Neurocrit Care       Date:  2013-12       Impact factor: 3.210

6.  Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization.

Authors:  Ross L Peterson; David M Vock; John H Powers; Sean Emery; Eduardo Fernandez Cruz; Sally Hunsberger; Mamta K Jain; Sarah Pett; James D Neaton
Journal:  Clin Trials       Date:  2017-03-06       Impact factor: 2.486

Review 7.  Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis.

Authors:  Gillian M Sare; Laura J Gray; Philip M W Bath
Journal:  Eur Heart J       Date:  2008-07-03       Impact factor: 29.983

8.  Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.

Authors:  Philip M W Bath; Katie Robson; Lisa J Woodhouse; Nikola Sprigg; Robert Dineen; Stuart Pocock
Journal:  Int J Stroke       Date:  2014-12-30       Impact factor: 5.266

9.  Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388).

Authors:  Kailash Krishnan; Maia Beridze; Hanne Christensen; Rob Dineen; Lelia Duley; Stan Heptinstall; Marilyn James; Hugh S Markus; Stuart Pocock; Annemarei Ranta; Thompson Robinson; Nikola Nikola; Graham Venables; Philip Bath
Journal:  Int J Stroke       Date:  2015-06-16       Impact factor: 5.266

10.  A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.

Authors:  Nikola Sprigg; Laura J Gray; Tim England; Mark R Willmot; Lian Zhao; Gillian M Sare; Philip M W Bath
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.